LYLu Yang

Lu Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lu Yang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Yanzhuo Liu

    School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    8 shared publications
  • Yan Teng

    Department of Neurology & Institute of Neurology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

    6 shared publications
  • Xingmin Chen

    School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    5 shared publications
  • Gaoping Zhao

    Department of Gastrointestinal Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, China

    4 shared publications
  • Zhihao Liu

    School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    4 shared publications
  • Fan Geng

    School of Medicine University of Electronic Science and Technology of China Chengdu Sichuan China

    3 shared publications

Latest Publications

  • Open Access

    Loss of METTL14 in dopaminergic neurons disrupts ER homeostasis via m6A-dependent regulation of Atp2a3 mRNA: Implications for Parkinson’s Disease

    by Yan Teng, Zhihao Liu, Fan Wei, Qin Tang, Manjun Li, Xingmin Chen, Jin Yi, Shu He, Jianli Xu, Yuqing Hang, et al.

    Dopaminergic (DA) neurons are highly susceptible to endoplasmic reticulum (ER) burden and redox imbalance, which drive their degeneration and contribute to Parkinson’s disease (PD) pathogenesis. Previous work established METTL14-mediated N6-methyladenosine (m6A) modification as critical for dopaminergic (DA) neuron survival. Here, we delineate the underlying mechanism by which m6A dysregulation triggers neurodegeneration through the post-transcriptional modulation of key target genes. Using Mettl14 conditional knockout mice, we identified the ER calcium channel ATP2A3—a key calcium homeostasis regulator and known PD biomarker—as a major target of METTL14. METTL14 deficiency significantly reduced ATP2A3 expression, thereby exacerbating ER homeostasis and oxidative stress, ultimately leading to DA neuronal death. Restoring METTL14 in vivo alleviates motor deficits and neurodegeneration. Our findings reveal that m6A-mediated regulation of ATP2A3 bridges RNA epigenetic dysregulation to PD pathogenesis, highlighting this axis as a potential therapeutic target in this disease.


  • Astrocytic Mettl14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice: targeting neuroinflammation in Alzheimer’s disease

    by Yan Teng, Jianli Xu, Shu He, Jin Yi, Manjun Li, Qin Tang, Xingmin Chen, Fan Wei, Yanzhuo Liu, Haisong Jiang, et al.

    Alzheimer’s disease (AD), a leading cause of dementia, represents a critical unmet global medical need. While the precise mechanisms underlying AD pathogenesis remain elusive, increasing evidence underscores the pivotal role of neuroinflammation in driving cognitive impairment. N6-methyladenosine (m6A), an epigenetic modification regulating RNA metabolism, has been found to be dysregulated in AD. In this study, we used a Mettl14 conditional knockout APP/PS1 mouse model (AD-cKO mice) to investigate the effects of modulating astrocytic m6A levels on AD progression. Our comprehensive histological, biochemical, and transcriptomic analyses revealed that AD-cKO mice exhibited enhanced cognitive function, along with decreased astrogliosis and reduced neuroinflammation when compared to APP/PS1 control mice. Based on the conjoint analysis of MeRIP-seq and RNA-seq data, our mechanistic studies further demonstrated that the loss of Mettl14 in astrocytes significantly affected the expression of DUSP1, a negative regulator of inflammation, to mitigate MAPK signaling. These findings suggest that targeting m6A regulators, such as Mettl14, may represent a promising therapeutic strategy to control neuroinflammation in AD progression. This study also highlights the broader potential of epigenetic modulation as a novel approach for treating AD. This graphic abstract illustrates the impact of Mettl14-mediated m6A modification on Alzheimer’s disease (AD) pathogenesis. Alzheimer’s disease, a leading cause of dementia, involves significant neuroinflammation. The study utilizes a Mettl14 conditional knockout APP/PS1 mouse model (AD-cKO mice) to investigate the role of m6A modification in astrocytes, the findings suggest that targeting m6A regulators like Mettl14 offers potential therapeutic benefits for controlling neuroinflammation in AD.


  • Open Access

    Reduction of DNA Topoisomerase Top2 reprograms the epigenetic landscape and extends health and life span across species

    by Man Zhu, Meng Ma, Lunan Luo, Feiyang Li, Jiashun Zhang, Yan Pan, Lu Yang, Ying Xiao, Ziyan Wang, Bo Xian, et al.

    DNA topoisomerases are essential molecular machines that manage DNA topology in the cell and play important roles in DNA replication and transcription. We find that knocking down the enzyme Topoisomerase Top2 or its mammalian homolog Top2b increases the life span of S. cerevisiae, C. elegans, and mice. Top2b reduction also extends the health span of mice and alleviates the pathologies of aging in multiple tissues. At the cellular/molecular level, Top2b reduction attenuates the major hallmarks of aging, such as cellular senescence, de-regulated nutrient sensing, epigenetic alteration, and lysosomal biogenesis. We observed that Top2b reduction significantly changes the epigenetic landscape in various mouse tissues toward those of the young animals, and differentially down-regulates genes with active promoter and high expression. Our observations suggest that Top2 reduction confers longevity effect across species via a conserved mechanism, and may be used as a novel therapeutic strategy for countering aging.

  • Open Access

    Downregulation of N6-methyladenosine (m6A) methylation of Sema4D mRNA contributes to Treg dysfunction and allograft rejection

    by Yanzhuo Liu, Qiang Fu, Maozhu Yang, Jianli Xu, Zili Zhou, Xingmin Chen, Yanling Zhang, Hao Yuan, Guiqing Jia, Shu He, et al.


  • Open Access

    Reduction of DNA Topoisomerase Top2 reprograms the epigenetic landscape and extends health and life span across species

    by Man Zhu, Meng Ma, Lunan Luo, Feiyang Li, Jiashun Zhang, Yan Pan, Lu Yang, Ying Xiao, Ziyan Wang, Bo Xian, et al.

    DNA topoisomerases are essential molecular machines that manage DNA topology in the cell and play important roles in DNA replication and transcription. We find that knocking down the enzyme Topoisomerase Top2 or its mammalian homolog Top2b increases the life span of S. cerevisiae , C. elegans , and mice. Top2b reduction also extends the health span of mice and alleviates the pathologies of aging in multiple tissues. At the cellular/molecular level, Top2b reduction attenuates the major hallmarks of aging, such as cellular senescence, de-regulated nutrient sensing, epigenetic alteration, and lysosomal biogenesis. We observed that Top2b reduction significantly changes the epigenetic landscape in various mouse tissues toward those of the young animals, and differentially down-regulates genes with active promoter and high expression. Our observations suggest that Top2 reduction confers longevity effect across species via a conserved mechanism, and may be used as a novel therapeutic strategy for countering aging.

  • Open Access

    N6-Methyladenosine (m6A) Modification in Natural Immune Cell-Mediated Inflammatory Diseases

    by Yan Teng, Jin Yi, Junnian Chen, Lu Yang

    The post-transcriptional N6-methyladenosine (m6A) modification of RNA influences stability, transport, and translation with implications for various physiological and pathological processes. Immune cell development, differentiation, and activation are also thought to be regulated by m6A and affect host defense against pathogens and inflammatory response with impacts on infectious, neoplastic, autoimmune, cardiovascular, hepatic, and osteal diseases. The current review summarizes recent research on m6A in monocyte/macrophages, neutrophils, dendritic cells, natural killer cells, and microglia and gives insights into epigenetic modifications of the immune system and novel therapeutic strategies for immune-related diseases.


  • Open Access

    The role of exosomes in adult neurogenesis: implications for neurodegenerative diseases

    by Zhuoyang Yu, Yan Teng, Jing Yang, Lu Yang

    Exosomes are cup-shaped extracellular vesicles with a lipid bilayer that is approximately 30 to 200 nm in thickness. Exosomes are widely distributed in a range of body fluids, including urine, blood, milk, and saliva. Exosomes exert biological function by transporting factors between different cells and by regulating biological pathways in recipient cells. As an important form of intercellular communication, exosomes are increasingly being investigated due to their ability to transfer bioactive molecules such as lipids, proteins, mRNAs, and microRNAs between cells, and because they can regulate physiological and pathological processes in the central nervous system. Adult neurogenesis is a multistage process by which new neurons are generated and migrate to be integrated into existing neuronal circuits. In the adult brain, neurogenesis is mainly localized in two specialized niches: the subventricular zone adjacent to the lateral ventricles and the subgranular zone of the dentate gyrus. An increasing body of evidence indicates that adult neurogenesis is tightly controlled by environmental conditions with the niches. In recent studies, exosomes released from different sources of cells were shown to play an active role in regulating neurogenesis both in vitro and in vivo , thereby participating in the progression of neurodegenerative disorders in patients and in various disease models. Here, we provide a state-of-the-art synopsis of existing research that aimed to identify the diverse components of exosome cargoes and elucidate the therapeutic potential of exosomal contents in the regulation of neurogenesis in several neurodegenerative diseases. We emphasize that exosomal cargoes could serve as a potential biomarker to monitor functional neurogenesis in adults. In addition, exosomes can also be considered as a novel therapeutic approach to treat various neurodegenerative disorders by improving endogenous neurogenesis to mitigate neuronal loss in the central nervous system.


  • Mettl14 sustains FOXP3 expression to promote the differentiation and functions of induced-regulatory T cells via the mTOR signaling pathway

    by Yanzhuo Liu, Yinglin Yuan, Zili Zhou, Xiaomei Jiang, Shu He, Fan Wei, Yuanyuan Cui, Lu Yang, Gaoping Zhao


  • Open Access

    Corrigendum: Mettl14-mediated m6A modification enhances the function of Foxp3+ regulatory T cells and promotes allograft acceptance

    by Yanzhuo Liu, Yinglin Yuan, Zili Zhou, Yuanyuan Cui, Yan Teng, Hao Huang, Hao Yuan, Yanling Zhang, Lu Yang, Gaoping Zhao

    Corrigendum: Mettl14-mediated m6A modification enhances the function of Foxp3+ regulatory T cells and promotes allograft acceptance